Articles from City Therapeutics

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public offering of 11,111,111 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the offering to City are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by City. In addition, City has granted the underwriters a 30-day option to purchase up to an additional 1,666,666 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by City.

City Therapeutics, Inc. (City), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the appointments of Keith Regnante, MBA, as Chief Financial Officer, and Mary Beth DeLena, J.D., as Chief Legal Officer. Mr. Regnante will lead the company’s finance organization and capital strategy, and Ms. DeLena will oversee legal affairs and corporate governance as City continues to expand its next-generation RNAi platform and pipeline.